REDEFINE 4 was an 84-week open-label Phase 3 study in 809 adults with obesity and at least one comorbidity, with a mean baseline weight of 114.2 kg
A method for preventing drug-induced ototoxicity in an individual in need thereof comprising intratympanic administration of a pharmaceutical composition comprising a therapeutic agent, wherein the therapeutic agent is an antioxidant or anti-apoptotic agent, wherein the pharmaceutical composition is administered prior to onset of therapy with the drug, and wherein the composition provides sustained release of the therapeutic agent into the ear for a period of at least 5 days after a single administration
Typical ranges from individual peptide research: BPC-157 in rat studies : 10 mcg/kg most common (range: 1-1000 mcg/kg) TB-500 in mouse studies : 10-100 mcg/kg typical range Combination protocols (anecdotal clinical use only): Often 1:1 ratio by mass
For both of these variables, the combined treatment of semaglutide and cagrilintide were shown to be more effective than either peptide treatment alone
Ruiz Ortiz M, Muniz J, Rana Miguez P, Roldan I, Marin F, Asuncion Esteve-Pastor M, et al
Abstract In heart disturbances, stable gastric pentadecapeptide BPC 157 especial therapy effects combine the therapy of myocardial infarction, heart failure, pulmonary hypertension arrhythmias, and thrombosis prevention and reversal
